文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

免疫治疗反应诱导肝细胞癌中三级淋巴样结构形态的差异。

Immunotherapy response induces divergent tertiary lymphoid structure morphologies in hepatocellular carcinoma.

机构信息

Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, MD, USA.

Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Johns Hopkins University, Baltimore, MD, USA.

出版信息

Nat Immunol. 2024 Nov;25(11):2110-2123. doi: 10.1038/s41590-024-01992-w. Epub 2024 Oct 25.


DOI:10.1038/s41590-024-01992-w
PMID:39455893
Abstract

Tertiary lymphoid structures (TLS) are associated with improved response in solid tumors treated with immune checkpoint blockade, but understanding of the prognostic and predictive value of TLS and the circumstances of their resolution is incomplete. Here we show that in hepatocellular carcinoma treated with neoadjuvant immunotherapy, high intratumoral TLS density at the time of surgery is associated with pathologic response and improved relapse-free survival. In areas of tumor regression, we identify a noncanonical involuted morphology of TLS marked by dispersion of the B cell follicle, persistence of a T cell zone enriched for T cell-mature dendritic cell interactions and increased expression of T cell memory markers. Collectively, these data suggest that TLS can serve as both a prognostic and predictive marker of response to immunotherapy in hepatocellular carcinoma and that late-stage TLS may support T cell memory formation after elimination of a viable tumor.

摘要

三级淋巴结构 (TLS) 与接受免疫检查点阻断治疗的实体瘤的疗效改善相关,但对于 TLS 的预后和预测价值以及其消退情况的理解尚不完全。在这里,我们发现,在接受新辅助免疫治疗的肝细胞癌中,手术时肿瘤内高 TLS 密度与病理反应和无复发生存期改善相关。在肿瘤消退区域,我们鉴定出一种非典型的 TLS 退化形态,其特征是 B 细胞滤泡弥散、富含 T 细胞-成熟树突状细胞相互作用的 T 细胞区的持续存在以及 T 细胞记忆标志物的表达增加。总的来说,这些数据表明,TLS 可以作为肝细胞癌对免疫治疗反应的预后和预测标志物,晚期 TLS 可能在消除存活肿瘤后支持 T 细胞记忆形成。

相似文献

[1]
Immunotherapy response induces divergent tertiary lymphoid structure morphologies in hepatocellular carcinoma.

Nat Immunol. 2024-11

[2]
Spatial characterization of tertiary lymphoid structures as predictive biomarkers for immune checkpoint blockade in head and neck squamous cell carcinoma.

Oncoimmunology. 2025-12

[3]
Tertiary lymphoid structures in esophageal cancer: a novel target for immunotherapy.

Front Immunol. 2025-6-4

[4]
Tertiary lymphoid structures in desmoplastic melanoma have increased lymphocyte density, lymphocyte proliferation, and immune cross talk with tumor when compared to non-desmoplastic melanomas.

Oncoimmunology. 2023

[5]
Mature tertiary lymphoid structures linked to HPV status and anti-PD-1 based chemoimmunotherapy response in head and neck squamous cell carcinoma.

Oncoimmunology. 2025-12

[6]
Identification of a risk score model based on tertiary lymphoid structure-related genes for predicting immunotherapy efficacy in non-small cell lung cancer.

Thorac Cancer. 2024-5

[7]
Genomic Characteristics Related to Histology-Based Immune Features in Breast Cancer.

Mod Pathol. 2025-5

[8]
Targeting USP47 enhances immunotherapy in hepatocellular carcinoma by destabilizing PD-L1.

Int Immunopharmacol. 2025-8-28

[9]
Interferon-responsive HEVs drive tumor tertiary lymphoid structure formation and predict immunotherapy response in nasopharyngeal carcinoma.

Cell Rep Med. 2025-7-15

[10]
Tertiary Lymphoid Structures Correlate With Better Prognosis in Patients With Retroperitoneal Sarcoma: A Retrospective Study.

Int J Urol. 2025-7

引用本文的文献

[1]
Tertiary lymphoid structures correlate with the therapeutic efficacy and prognosis of resectable esophageal squamous cell carcinoma undergoing neoadjuvant chemoradiotherapy plus immunotherapy.

Front Immunol. 2025-8-22

[2]
Tissue-Resident T Cells That Promote Humoral Immunity: Emerging From the Shadow of T Follicular Helper Cells.

Immunol Rev. 2025-9

[3]
Sustained immune youth risks autoimmune disease in the aging host.

Nat Aging. 2025-8

[4]
Noninvasive MRI imaging feature-based prediction of intratumoral tertiary lymphoid structure maturity in hepatocellular carcinoma: a multicenter retrospective study.

Eur Radiol. 2025-8-6

[5]
Spatial multi-omics and deep learning reveal fingerprints of immunotherapy response and resistance in hepatocellular carcinoma.

bioRxiv. 2025-6-12

[6]
Mature tertiary lymphoid structures linked to HPV status and anti-PD-1 based chemoimmunotherapy response in head and neck squamous cell carcinoma.

Oncoimmunology. 2025-12

[7]
The Sunrise of Tertiary Lymphoid Structures in Cancer.

Immunol Rev. 2025-7

[8]
Perivascular Tertiary Lymphoid Structures in Autoimmune Disease.

Immunol Rev. 2025-7

[9]
Bridging Immune Evasion and Vascular Dynamics for Novel Therapeutic Frontiers in Hepatocellular Carcinoma.

Cancers (Basel). 2025-5-31

[10]
Recent advances in therapeutic cancer vaccines.

Nat Rev Cancer. 2025-5-16

本文引用的文献

[1]
Tertiary lymphoid structures and B cells: An intratumoral immunity cycle.

Immunity. 2023-10-10

[2]
Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy.

Cancer Cell. 2023-9-11

[3]
Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma.

N Engl J Med. 2023-3-2

[4]
Single-cell meta-analyses reveal responses of tumor-reactive CXCL13 T cells to immune-checkpoint blockade.

Nat Cancer. 2022-9

[5]
Profiling of syngeneic mouse HCC tumor models as a framework to understand anti-PD-1 sensitive tumor microenvironments.

Hepatology. 2023-5-1

[6]
Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort.

Nat Med. 2022-6

[7]
CXCL13-producing CD4+ T cells accumulate in the early phase of tertiary lymphoid structures in ovarian cancer.

JCI Insight. 2022-6-22

[8]
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.

N Engl J Med. 2022-5-26

[9]
New Insights of CCR7 Signaling in Dendritic Cell Migration and Inflammatory Diseases.

Front Pharmacol. 2022-2-25

[10]
Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer.

Immunity. 2022-3-8

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索